Jump to content

Publication: The chemopreventive effect of Ginkgo biloba extract 761 against cisplatin ototoxicity: a pilot study

From CAMIH
Revision as of 09:40, 15 July 2024 by JDoerfler (talk | contribs) (Created page with "{{Publication |Title=The chemopreventive effect of Ginkgo biloba extract 761 against cisplatin ototoxicity: a pilot study |Topic=Ginkgo |Author=Dias, MA; Sampaio, ALL; Venosa, AR; Meneses, EA; Oliveira, CACP |Year=2015 |Journal=International Tinnitus Journal |DOI=https://doi.org/10.5935/0946-5448.20150003 |Authors Abstract=Objective: The purpose of this study was to evaluate, by using distortion product otoacoustic emission test, the action of Ginkgo biloba extract 761,...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)


Reference
Title The chemopreventive effect of Ginkgo biloba extract 761 against cisplatin ototoxicity: a pilot study
Topic Ginkgo
Author Dias, MA, Sampaio, ALL, Venosa, AR, Meneses, EA, Oliveira, CACP
Year 2015
Journal International Tinnitus Journal
DOI https://doi.org/10.5935/0946-5448.20150003

Author's Abstract The abstract and the information and conclusions contained therein were written by the authors of the publication.

Objective: The purpose of this study was to evaluate, by using distortion product otoacoustic emission test, the action of Ginkgo biloba extract 761, which has a known antioxidant property, as a possible otoprotective against cisplatin-induced hearing loss. This prospective and double-blinded study was conducted on individuals that were to begin cisplatin treatment in a tertiary university center. They were randomized and allocated into two groups: control group (CG) (n=07) receiving placebo and cisplatin and study group (SG) (n=08) receiving Ginkgo biloba extract 761 (240 mg/day) and cisplatin.

Methods: This prospective study was conducted on individuals that were treated for cancer with cisplatin (CDDP) in a tertiary university center. Both groups were instructed to ingest either placebo or Ginkgo biloba extract 761 before the first cisplatin dose. They were rated and followed up for approximately 90 days. The maximum cumulative cisplatin dosage was 300 mg/m². The ototoxic effect was measured with distortion product otoacoustic emissions. Distortion product otoacoustic emissions were recorded before the first cisplatin cycle, and 30, 60, and 90 days after the treatment. The average of the amplitude of the signals was calculated and used for comparisons between the groups.

Results: Comparisons were made between baseline measurements and those recorded after the maximum cumulative CDDP dose. The control group showed smaller distortion product otoacoustic emissions mean amplitudes and smaller signal/noise ratio than the study group (p<0.05).

Conclusion: Ginkgo biloba extract 761 probably has antioxidant properties and might play an otoprotective role against cisplatin ototoxicity in these patients.



This publication is referenced in the following studies:

  1. Dias et al. (2015): The chemopreventive effect of Ginkgo biloba extract 761 against cisplatin ototoxicity: a pilot study